STOCK TITAN
  1. Home
  2. Sec-filings
  3. ENGN
  4. [EFFECT] enGene Holdings Inc. SEC Filing

[EFFECT] enGene Holdings Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 2, 2026 4:00 P.M.
Form: S-3
CIK: 0001980845
Company Name: enGene Holdings Inc.
File Number: 333-293597

Source: View Original Filing on SEC EDGAR

Stock ENGN logo
enGene Holdings Inc.

NASDAQ:ENGN

ENGN Rankings

#3208 Ranked by Market Cap
N/A Ranked by Dividends

ENGN Latest News

Feb 20, 2026
enGene to Participate in Upcoming Investor Conferences
Feb 4, 2026
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Jan 20, 2026
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
Dec 22, 2025
enGene Reports Full Year 2025 Financial Results and Provides Business Update
Dec 2, 2025
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

ENGN Latest SEC Filings

Feb 19, 2026
[S-3] enGene Holdings Inc. Shelf Registration Statement
Feb 19, 2026
[10-K/A] enGene Holdings Inc. Amends Annual Report
Feb 17, 2026
[SCHEDULE 13G/A] enGene Holdings Inc. Amended Passive Investment Disclosure
Feb 17, 2026
[SCHEDULE 13G] enGene Holdings Inc. Passive Investment Disclosure (>5%)
Feb 17, 2026
[SCHEDULE 13G/A] enGene Holdings Inc. Amended Passive Investment Disclosure

ENGN Stock Data

677.21M
61.03M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
Canada
SAINT-LAURENT